Rosario Vasta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2583013/publications.pdf Version: 2024-02-01



POSADIO VASTA

#	Article	IF	CITATIONS
1	Aging and Parkinson's Disease: Inflammaging, neuroinflammation and biological remodeling as key factors in pathogenesis. Free Radical Biology and Medicine, 2018, 115, 80-91.	2.9	255
2	Sex Differences in Clinical and Genetic Determinants of Levodopa Peak-Dose Dyskinesias in Parkinson Disease. Archives of Neurology, 2005, 62, 601.	4.5	195
3	Cognitive-motor dual-task interference: A systematic review of neural correlates. Neuroscience and Biobehavioral Reviews, 2017, 75, 348-360.	6.1	179
4	Metals and neurodegenerative diseases. A systematic review. Environmental Research, 2017, 159, 82-94.	7.5	178
5	Identification of circulating microRNAs for the differential diagnosis of Parkinson's disease and Multiple System Atrophy. Frontiers in Cellular Neuroscience, 2014, 8, 156.	3.7	150
6	Cognitive impairment across ALS clinical stages in a population-based cohort. Neurology, 2019, 93, e984-e994.	1.1	115
7	Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Movement Disorders, 2001, 16, 197-201.	3.9	111
8	The dopamine D2 receptor gene is a susceptibility locus for Parkinson's disease. Movement Disorders, 2000, 15, 120-126.	3.9	108
9	ALS phenotype is influenced by age, sex, and genetics. Neurology, 2020, 94, e802-e810.	1.1	99
10	Hormetic approaches to the treatment of Parkinson's disease: Perspectives and possibilities. Journal of Neuroscience Research, 2018, 96, 1641-1662.	2.9	75
11	Basal ganglia calcifications (Fahr's syndrome): related conditions and clinical features. Neurological Sciences, 2019, 40, 2251-2263.	1.9	73
12	Body Weight Influences Pharmacokinetics of Levodopa in Parkinson's Disease. Clinical Neuropharmacology, 2002, 25, 79-82.	0.7	71
13	Long-duration response to levodopa influences the pharmacodynamics of short-duration response in Parkinson's disease. Annals of Neurology, 1997, 42, 245-248.	5.3	63
14	Incidence of Mild Cognitive Impairment and Dementia in Parkinson's Disease: The Parkinson's Disease Cognitive Impairment Study. Frontiers in Aging Neuroscience, 2019, 11, 21.	3.4	62
15	The subacute levodopa test for evaluating long-duration response in parkinson's disease. Annals of Neurology, 1995, 38, 389-395.	5.3	60
16	Mild Non-lesional Temporal Lobe Epilepsy: A Common, Unrecognized Disorder with Onset in Adulthood. Canadian Journal of Neurological Sciences, 1998, 25, 282-286.	0.5	55
17	Gender effect on non-motor symptoms in Parkinson's disease: are men more at risk?. Parkinsonism and Related Disorders, 2017, 35, 69-74.	2.2	53
18	Short-term levodopa test assessed by movement time accurately predicts dopaminergic responsiveness in Parkinson's disease. Movement Disorders, 1997, 12, 103-106.	3.9	46

#	Article	IF	CITATIONS
19	Changes in Motor, Cognitive, and Behavioral Symptoms in Parkinson's Disease and Mild Cognitive Impairment During the COVID-19 Lockdown. Frontiers in Psychiatry, 2020, 11, 590134.	2.6	46
20	Increased Risk for Alzheimer Disease With the Interaction of MPO and A2M Polymorphisms. Archives of Neurology, 2004, 61, 341.	4.5	45
21	Migraine causes retinal and choroidal structural changes: evaluation with ocular coherence tomography. Journal of Neurology, 2017, 264, 494-502.	3.6	43
22	Vitamin E deficiency due to chylomicron retention disease in Marinesco-Sj�gren syndrome. Annals of Neurology, 2000, 47, 260-264.	5.3	40
23	Apolipoprotein E Polymorphisms and the Risk of Nonlesional Temporal Lobe Epilepsy. Epilepsia, 1999, 40, 1804-1807.	5.1	36
24	Patient perspectives on the acceptability of mHealth technology for remote measurement and management of epilepsy: A qualitative analysis. Epilepsy and Behavior, 2019, 97, 123-129.	1.7	36
25	An update on idiopathic intracranial hypertension in adults: a look at pathophysiology, diagnostic approach and management. Journal of Neurology, 2021, 268, 3249-3268.	3.6	36
26	Voluptuary habits and clinical subtypes of Parkinson's disease: The FRAGAMP case–control study. Movement Disorders, 2010, 25, 2387-2394.	3.9	35
27	The epidemiology of amyotrophic lateral sclerosis in the Mount Etna region: a possible pathogenic role of volcanogenic metals. European Journal of Neurology, 2016, 23, 964-972.	3.3	34
28	Increasing the Coding Potential of Genomes Through Alternative Splicing: The Case of PARK2 Gene. Current Genomics, 2014, 15, 203-216.	1.6	32
29	Unraveling the complex interplay between genes, environment, and climate in ALS. EBioMedicine, 2022, 75, 103795.	6.1	32
30	Reproductive factors and Parkinson's disease: A multicenter case–control study. Movement Disorders, 2011, 26, 2563-2566.	3.9	31
31	Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease. Journal of Neurology, 2016, 263, 888-894.	3.6	29
32	Vascular risk factors, white matter lesions and cognitive impairment in Parkinson's disease: the PACOS longitudinal study. Journal of Neurology, 2021, 268, 549-558.	3.6	28
33	Iron and Parkinson's disease: A systematic review and meta-analysis. Molecular Medicine Reports, 2017, 15, 3383-3389.	2.4	27
34	Telemedicine for patients with amyotrophic lateral sclerosis during COVID-19 pandemic: an Italian ALS referral center experience. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 308-311.	1.7	27
35	Retinal Thickness and Microvascular Pattern in Early Parkinson's Disease. Frontiers in Neurology, 2020, 11, 533375.	2.4	26
36	Prevalence of idiopathic REM behavior disorder: a systematic review and meta-analysis. Sleep, 2021, 44, .	1.1	26

#	Article	IF	CITATIONS
37	CSF Nâ€glycan profile reveals sialylation deficiency in a patient with GM2 gangliosidosis presenting as childhood disintegrative disorder. Autism Research, 2016, 9, 423-428.	3.8	25
38	Parkinsonian traits in amyotrophic lateral sclerosis (ALS): a prospective population-based study. Journal of Neurology, 2019, 266, 1633-1642.	3.6	25
39	Single Photon Emission Computed Tomography Striatal Asymmetry Index May Predict Dopaminergic Responsiveness in Parkinson Disease. Clinical Neuropharmacology, 2011, 34, 71-73.	0.7	24
40	Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS ONE, 2017, 12, e0180651.	2.5	24
41	Clinical and Electrophysiological Hints to TMS in De Novo Patients with Parkinson's Disease and Progressive Supranuclear Palsy. Journal of Personalized Medicine, 2020, 10, 274.	2.5	24
42	Mutational Analysis of Known ALS Genes in an Italian Population-Based Cohort. Neurology, 2021, 96, e600-e609.	1.1	23
43	Knowledge, stigma, and quality of life in epilepsy: Results before and after a community-based epilepsy awareness program in rural Bolivia. Epilepsy and Behavior, 2019, 92, 90-97.	1.7	22
44	Side effects induced by the acute levodopa challenge in Parkinson's Disease and atypical parkinsonisms. PLoS ONE, 2017, 12, e0172145.	2.5	21
45	A Dynamic Bayesian Network model for the simulation of Amyotrophic Lateral Sclerosis progression. BMC Bioinformatics, 2019, 20, 118.	2.6	20
46	Identifying and predicting amyotrophic lateral sclerosis clinical subgroups: a population-based machine-learning study. The Lancet Digital Health, 2022, 4, e359-e369.	12.3	19
47	Negative Myoclonic Status Due to Antiepileptic Drug Tapering: Report of Three Cases. Epilepsia, 1997, 38, 819-823.	5.1	18
48	Regional spreading of symptoms at diagnosis as a prognostic marker in amyotrophic lateral sclerosis: a population-based study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 291-297.	1.9	18
49	Prognostic role of slow vital capacity in amyotrophic lateral sclerosis. Journal of Neurology, 2020, 267, 1615-1621.	3.6	18
50	The links between diabetes mellitus and amyotrophic lateral sclerosis. Neurological Sciences, 2021, 42, 1377-1387.	1.9	18
51	Neuroanatomical changes in early Parkinson's disease with mild cognitive impairment: a VBM study; the Parkinson's Disease Cognitive Impairment Study (PaCoS). Neurological Sciences, 2021, 42, 3723-3731.	1.9	18
52	CSF neurotoxic metals/metalloids levels in amyotrophic lateral sclerosis patients: comparison between bulbar and spinal onset. Environmental Research, 2020, 188, 109820.	7.5	17
53	Differential Neuropsychological Profile of Patients With Amyotrophic Lateral Sclerosis With and Without <i>C9orf72</i> Mutation. Neurology, 2021, 96, e141-e152.	1.1	17
54	Coffee consumption and risk of levodopaâ€induced dyskinesia in Parkinson's disease: The FRAGAMP study. Movement Disorders, 2015, 30, 1854-1856.	3.9	16

#	Article	IF	CITATIONS
55	Retinal thickness and microvascular pathway in Idiopathic Rapid eye movement sleep behaviour disorder and Parkinson's disease. Parkinsonism and Related Disorders, 2021, 88, 40-45.	2.2	16
56	The FRAGAMP study: environmental and genetic factors in Parkinson's disease, methods and clinical features. Neurological Sciences, 2010, 31, 47-52.	1.9	15
57	The interplay among education, brain metabolism, and cognitive impairment suggests a role of cognitive reserve in Amyotrophic Lateral Sclerosis. Neurobiology of Aging, 2021, 98, 205-213.	3.1	15
58	Amyotrophic lateral sclerosis caregiver burden and patients' quality of life during COVID-19 pandemic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 146-148.	1.7	15
59	Comic book-based educational program on epilepsy for high-school students: Results from a pilot study in the Gran Chaco region, Bolivia. Epilepsy and Behavior, 2020, 107, 107076.	1.7	14
60	Metabolic brain changes across different levels of cognitive impairment in ALS: a ¹⁸ F-FDG-PET study. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 357-363.	1.9	14
61	Validation of the UPDRS section IV for detection of motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2016, 27, 98-101.	2.2	13
62	Knowledge, attitudes, and practices towards epilepsy among general practitioners in rural Bolivia: Results before and after a training program on epilepsy. Epilepsy and Behavior, 2018, 83, 113-118.	1.7	13
63	The role of arterial blood gas analysis (ABG) in amyotrophic lateral sclerosis respiratory monitoring. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 999-1000.	1.9	13
64	Vascular Parkinsonism: Still Looking for a Diagnosis. Frontiers in Neurology, 2018, 9, 411.	2.4	12
65	Knowledge and attitudes towards epilepsy among nonmedical health workers in rural Bolivia: Results after a long-term activity in the Chaco region. Epilepsy and Behavior, 2018, 85, 58-63.	1.7	12
66	Mild Behavioral Impairment in Parkinson's Disease: Data from the Parkinson's Disease Cognitive Impairment Study (PACOS). Journal of Alzheimer's Disease, 2019, 68, 1603-1610.	2.6	12
67	Toxoplasma gondii and multiple sclerosis: a population-based case–control study. Scientific Reports, 2020, 10, 18855.	3.3	12
68	Relationship between risk and protective factors and clinical features of Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 80-85.	2.2	12
69	Head trauma and Parkinson's disease: results from an Italian case-control study. Neurological Sciences, 2017, 38, 1835-1839.	1.9	11
70	Magnetic fields exposure from high-voltage power lines and risk of amyotrophic lateral sclerosis in two Italian populations. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 583-589.	1.7	11
71	Cardiovascular autonomic function and MCI in Parkinson's disease. Parkinsonism and Related Disorders, 2019, 69, 55-58.	2.2	11
72	Transcranial random noise stimulation over the primary motor cortex in PD-MCI patients: a crossover, randomized, sham-controlled study. Journal of Neural Transmission, 2020, 127, 1589-1597.	2.8	11

#	Article	IF	CITATIONS
73	Plateaus in amyotrophic lateral sclerosis progression: results from a populationâ€based cohort. European Journal of Neurology, 2020, 27, 1397-1404.	3.3	11
74	Prevalence of isolated RBD in the city of Catania, Italy: a population-based study. Journal of Clinical Sleep Medicine, 2021, 17, 2241-2248.	2.6	11
75	Adult-Onset Sleepwalking Secondary to Hyperthyroidism: Polygraphic Evidence. Journal of Clinical Sleep Medicine, 2018, 14, 285-287.	2.6	10
76	Incidence of multiple sclerosis in the province of Catania. A geo-epidemiological study. Environmental Research, 2020, 182, 109022.	7.5	10
77	Brain metabolic changes across King's stages in amyotrophic lateral sclerosis: a 18F-2-fluoro-2-deoxy-d-glucose-positron emission tomography study. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 1124-1133.	6.4	10
78	Brain metabolic correlates of apathy in amyotrophic lateral sclerosis: An 18Fâ€FDGâ€positron emission tomography stud. European Journal of Neurology, 2021, 28, 745-753.	3.3	10
79	Photic-Induced Epileptic Negative Myoclonus: A Case Report. Epilepsia, 1996, 37, 492-494.	5.1	9
80	Clinical and radiologic rebound after discontinuation of natalizumab therapy in a highly active multiple sclerosis patient was not halted by dimethyl-fumarate: a case report. BMC Neurology, 2015, 15, 252.	1.8	9
81	Obsessive compulsive personality disorder in Progressive Supranuclear Palsy, Multiple System Atrophy and Essential Tremor. Parkinsonism and Related Disorders, 2016, 30, 36-39.	2.2	9
82	Validity of medico-administrative data related to amyotrophic lateral sclerosis in France: A population-based study. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2017, 18, 24-31.	1.7	9
83	Spatial epidemiology of amyotrophic lateral sclerosis in Piedmont and Aosta Valley, Italy: a populationâ€based cluster analysis. European Journal of Neurology, 2018, 25, 756-761.	3.3	9
84	Seroprevalence of Toxocara canis in the city of Catania, Italy Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019031.	1.3	9
85	Parasomnias, sleep-related movement disorders and physiological sleep variants in focal epilepsy: A polysomnographic study. Seizure: the Journal of the British Epilepsy Association, 2020, 81, 84-90.	2.0	9
86	Validation of the Italian version of self-administered ALSFRS-R scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 151-153.	1.7	9
87	Cognitive impairment and levodopa induced dyskinesia in Parkinson's disease: a longitudinal study from the PACOS cohort. Scientific Reports, 2021, 11, 867.	3.3	9
88	Amyotrophic lateral sclerosis with SOD1 mutations shows distinct brain metabolic changes. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 2242-2250.	6.4	9
89	The Characteristics of Cognitive Impairment in ALS Patients Depend on the Lateralization of Motor Damage. Brain Sciences, 2020, 10, 650.	2.3	8
90	What is amyotrophic lateral sclerosis prevalence?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 203-208.	1.7	8

Rosario Vasta

#	Article	IF	CITATIONS
91	Arterial blood gas analysis: base excess and carbonate are predictive of noninvasive ventilation adaptation and survival in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, 22, 33-39.	1.7	8
92	Opinion, knowledge, and clinical experience with functional neurological disorders among Italian neurologists: results from an online survey. Journal of Neurology, 2022, 269, 2549-2559.	3.6	8
93	Social cognition deficits in amyotrophic lateral sclerosis: A pilot crossâ€sectional populationâ€based study. European Journal of Neurology, 2022, 29, 2211-2219.	3.3	8
94	Respiratory support in a population-based ALS cohort: demographic, timing and survival determinants. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1024-1026.	1.9	8
95	Dopaminergic and non-dopaminergic gait components assessed by instrumented timed up and go test in Parkinson's disease. Journal of Neural Transmission, 2017, 124, 1539-1546.	2.8	7
96	Clinical and CN-SFEMG evaluation of neostigmine test in myasthenia gravis. Neurological Sciences, 2018, 39, 341-345.	1.9	7
97	Amyotrophic lateral sclerosis spatial epidemiology in the Mount Etna region, Italy. European Journal of Neurology, 2019, 26, e90-e91.	3.3	7
98	Lifetime sport practice and brain metabolism in Amyotrophic Lateral Sclerosis. NeuroImage: Clinical, 2020, 27, 102312.	2.7	7
99	Usefulness of a smartphone application for the diagnosis of epilepsy: Validation study in high-income and rural low-income countries. Epilepsy and Behavior, 2021, 115, 107680.	1.7	7
100	The heterozygous deletion c.1509_1510delAG in exon 14 of FUS causes an aggressive childhood-onset ALS with cognitive impairment. Neurobiology of Aging, 2021, 103, 130.e1-130.e7.	3.1	7
101	Executive functioning and serum lipid fractions in Parkinson's disease—a possible sex-effect: the PACOS study. Journal of Neural Transmission, 2022, 129, 287-293.	2.8	7
102	Incidence of amyotrophic lateral sclerosis in Sardinia, Italy: age–sex interaction and spatial–temporal variability. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 585-591.	1.7	7
103	Predicting functional impairment trajectories in amyotrophic lateral sclerosis: a probabilistic, multifactorial model of disease progression. Journal of Neurology, 2022, 269, 3858-3878.	3.6	7
104	Vascular parkinsonism or idiopathic NPH? New insights from CSF pressure analysis. Neurological Sciences, 2017, 38, 2209-2212.	1.9	6
105	Treating People With Epilepsy in Rural Low-Income Countries Is Feasible. Observations and Reflections From a "Real Life Experience―After a Long Lasting Intervention in the Rural Chaco. Frontiers in Neurology, 2018, 9, 855.	2.4	6
106	Asymmetry index of Blink Reflex Recovery Cycle differentiates Parkinson's disease from atypical Parkinsonian syndromes. Journal of Neurology, 2020, 267, 1859-1863.	3.6	6
107	Parkinsonism and cerebrospinal fluid disorders. Journal of the Neurological Sciences, 2022, 433, 120019.	0.6	6
108	Parkinsonism in idiopathic normal pressure hydrocephalus: is it time for defining a clinical tetrad?. Neurological Sciences, 2022, 43, 5201-5205.	1.9	6

#	Article	IF	CITATIONS
109	Electroclinical findings of minor motor events during sleep in temporal lobe epilepsy. Epilepsia, 2017, 58, 1261-1267.	5.1	5
110	Accuracy of MDS-UPDRS section IV for detecting motor fluctuations in Parkinson's disease. Neurological Sciences, 2019, 40, 1271-1273.	1.9	5
111	Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 914-920.	1.9	5
112	Pure sensitive chronic inflammatory axonal polyneuropathy following Pfizer COVID-19 vaccine. Neurological Sciences, 2022, 43, 1431-1433.	1.9	5
113	Quantitative estimation of motor fluctuations in Parkinson's disease. Parkinsonism and Related Disorders, 2017, 42, 34-39.	2.2	4
114	Febrile infection-related epilepsy syndrome (FIRES) in an adult patient: an early neuroradiological finding. Neurological Sciences, 2019, 40, 2407-2410.	1.9	4
115	Neck flexor weakness at diagnosis predicts respiratory impairment in amyotrophic lateral sclerosis. European Journal of Neurology, 2021, 28, 1181-1187.	3.3	4
116	Do ecological factors influence the clinical presentation of amyotrophic lateral sclerosis?. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 1017-1019.	1.9	4
117	Structural MRI substrate of long-duration response to levodopa in Parkinson's disease: an exploratory study. Journal of Neurology, 2021, 268, 4258-4264.	3.6	4
118	The impact of COVID-19 pandemic on frail health systems of low- and middle-income countries: The case of epilepsy in the rural areas of the Bolivian Chaco. Epilepsy and Behavior, 2021, 118, 107917.	1.7	4
119	Use of antipsychotics and long-term risk of parkinsonism. Neurological Sciences, 2021, , 1.	1.9	4
120	Brain ¹⁸ fluorodeoxyglucose-positron emission tomography changes in amyotrophic lateral sclerosis with <i>TARDBP</i> mutations. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 1021-1023.	1.9	4
121	Switching I-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's Disease. Clinical Neuropharmacology, 2017, 40, 6-10.	0.7	3
122	Lack of association between Toxocara canis and multiple sclerosis: A population-based case–control study. Multiple Sclerosis Journal, 2020, 26, 258-259.	3.0	3
123	Administration of subcutaneous interferon beta 1a in the evening: data from RELIEF study. Journal of Neurology, 2020, 267, 1812-1823.	3.6	3
124	A familial amyotrophic lateral sclerosis pedigree discordant for a novel p.Glu46Asp heterozygous OPTN variant and the p.Ala5Val heterozygous SOD1 missense mutation. Journal of Clinical Neuroscience, 2020, 75, 223-225.	1.5	3
125	GBA variants influence cognitive status in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 2021, , jnnp-2021-327426.	1.9	3
126	Causal associations of genetic factors with clinical progression in amyotrophic lateral sclerosis. Computer Methods and Programs in Biomedicine, 2022, 216, 106681.	4.7	3

Rosario Vasta

#	Article	IF	CITATIONS
127	A novel splice site FUS mutation in a familial ALS case: effects on protein expression. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-9.	1.7	2
128	Validation of the Italian version of the Rasch-Built Overall Amyotrophic Lateral Sclerosis Disability Scale (ROADS) administered to patients and their caregivers. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 424-429.	1.7	2
129	Dopamine D2 receptor Taql A polymorphism and Parkinson's disease. Movement Disorders, 2001, 16, 975-975.	3.9	1
130	Forehead Tremor: A Clinical Presentation of Myasthenia Gravis?. Movement Disorders Clinical Practice, 2018, 5, 225-226.	1.5	1
131	Burden of Parkinson's disease in Sicily: a health administrative database study. Neurological Sciences, 2022, 43, 1043-1046.	1.9	1
132	Tailoring patients' enrollment in ALS clinical trials: the effect of disease duration and vital capacity cutoffs. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2022, 23, 108-115.	1.7	1
133	Does an association between cigarette smoking and Parkinson's Disease-related psychosis exist? Insights from a large non-demented cohort. Journal of the Neurological Sciences, 2021, 427, 117509.	0.6	1
134	Can amyotrophic lateral sclerosis progression really pause? A cohort study using the medical research council scale. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2021, , 1-7.	1.7	1
135	Comorbidity of Cervical Spondylogenic Myelopathy and Amyotrophic Lateral Sclerosis: When Electromyography Makes the Difference in Diagnosis. European Neurology, 2020, 83, 626-629.	1.4	1
136	Spinal needle and post-dural puncture headache. Neurological Sciences, 2022, 43, 1467-1468.	1.9	1
137	Influence of Drugs on Mild Cognitive Impairment in Parkinson's Disease: Evidence from the PACOS Study. Current Neuropharmacology, 2021, 20, .	2.9	1
138	Response to the letter: "Obsessive compulsive personality disorder in Progressive Supranuclear Palsy― by Golimstok. Parkinsonism and Related Disorders, 2016, 33, 144-145.	2.2	0
139	Video analysis of epileptic-like motor patterns in REM behaviour disorder: a case series. Neurological Sciences, 2017, 38, 699-701.	1.9	0
140	Neuroticism and Risk of Parkinson's Disease: A <scp>Metaâ€Analysis</scp> . Movement Disorders, 2021, 36, 2215-2215.	3.9	0
141	Impulsivity traits in eyelid myoclonia with absences. Seizure: the Journal of the British Epilepsy Association, 2021, 91, 393-396.	2.0	0
142	Incidence and spatial distribution of adult-onset primary malignant and other central nervous system tumors in Southern Sardinia, Italy. Neurological Sciences, 2022, 43, 419-425.	1.9	0
143	Obsessive–compulsive personality disorder in rapid eye movement sleep behavior disorder. Scientific Reports, 2022, 12, 2401.	3.3	0
144	Morphometric magnetic resonance imaging corticoâ€subcortical features in Parkinson's disease with mild cognitive impairment. European Journal of Neurology, 0, , .	3.3	0